Summit Therapeutics SMMT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$189.42M-201% | -$219.17M-258% | -$231.79M-312% | -$565.71M-837% | -$62.91M-44.7% | ||
| $44K+76.0% | $42K+90.9% | $42K+110% | $37K+85.0% | $25K-7.4% | ||
| $72.79M+556% | $111.78M+915% | $130.76M+575% | $478.78M+4,218% | $11.1M+16.7% | ||
| $6.8M+1,811% | —— | —— | $17.93M— | $356K-90.4% | ||
| $12.22M+658% | $5.53M+143% | $945K-84.0% | $4.84M-18.4% | $1.61M+172% | ||
| $1.03M-27.7% | -$9.39M-196% | $856K+6,214% | $2.25M+56,225% | $1.42M+158% | ||
| -$33K-232% | $0-100% | $30K+25.0% | $27K— | $25K-98.6% | ||
| -$122.29M-99.9% | -$101.94M-109% | -$93.08M-207% | -$66.74M-102% | -$61.17M-103% | ||
| $245K-41.9% | $164K+1,071% | $71K+22.4% | $0-100% | $422K+10,450% | ||
| $177.29M— | $484.99M+224% | $0-100% | $0-100% | $0-100% | ||
| $177.29M+10.4% | —— | —— | $150.81M+115% | $160.53M+42.2% | ||
| -$238K-100% | -$485.16M— | -$71K+99.9% | $150.81M+175% | $160.11M+706% | ||
| $3.8M+88.1% | $1.02M+106% | $2.05M-8.5% | $565K— | $2.02M— | ||
| $3.8M-50.5% | $573.82M— | $33.81M-83.4% | $2.22M-98.9% | $7.68M+1,483% | ||
| -$19K-150% | —— | $22K-80.7% | $61K— | $38K+206% | ||
| -$118.75M-211% | —— | —— | $86.35M+363% | $106.66M+1,187% | ||
| $4.22M+42.2% | $3.02M— | $0-100% | $1.02M-36.3% | $2.97M+638% | ||
| $44K+76.0% | $42K+90.9% | $42K+110% | $37K+85.0% | $25K-7.4% | ||
| -$190K-185% | —— | —— | $239K+92.7% | $224K+2,589% | ||
| -$7.85M-3.5% | $3.96M-2.1% | —— | —— | -$7.59M-1,352% | ||
| $365K+1,360% | $267K— | —— | —— | $25K-72.8% | ||
| -$1.14M-8.5% | —— | $476K+136% | —— | -$1.05M-1,178% | ||
| -$33K-232% | $0-100% | $30K+25.0% | $27K— | $25K-98.6% | ||
| $11.01M+695% | -$1.21M-115% | -$3.74M-4,448% | $1.93M+162% | -$1.85M-189% | ||
| $177.29M— | $484.99M+224% | $0-100% | $0-100% | $0-100% | ||
| $177.29M+10.4% | —— | —— | $150.81M+115% | $160.53M+42.2% | ||
| $3.8M+88.1% | $1.02M+106% | $2.05M+24.6% | $565K+409% | $2.02M+316% | ||
| $0-100% | —— | —— | $1.66M+1,541% | $5.66M— | ||
| $746K— | $127K— | $92K— | $72K— | $0— | ||
| -$122.54M-99.0% | -$102.1M-110% | -$93.15M-207% | -$66.74M-102% | -$61.59M-104% | ||
| -$122.54M-99.0% | -$102.1M-110% | -$93.15M-207% | -$66.74M-102% | -$61.59M-104% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Summit Therapeutics generate?
- Summit Therapeutics (SMMT) generated -$384.1M in operating cash flow over the trailing twelve months.
- What is Summit Therapeutics's free cash flow?
- After $480.0K of capital expenditures, Summit Therapeutics's free cash flow was -$384.5M over the trailing twelve months, down 121.4% year over year.
- Where does Summit Therapeutics's cash flow data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.